Skip to main content

Table 2 Association among gene polymorphisms and risk of severe toxicity (grade 3–4 vs. 0–1-2)

From: Influence of chemotherapeutic drug-related gene polymorphisms on toxicity and survival of early breast cancer patients receiving adjuvant chemotherapy

 

HEMATOLOGIC TOXICITY

NON-HEMATOLOGIC TOXICITY

LEUCOPENIA

NEUTROPENIA

STOMATITIS

HEPATIC

Genotype

0–1-2

3–4

OR (95%CI)

p

0–1-2

3–4

OR (95%CI)

P

0–1-2

3–4

OR (95%CI)

p

0–1-2

3–4

OR (95%CI)

p

GSTT1

 null

47

3

1 (reference)

0.155

45

5

1 (reference)

0.349

49

1

1 (reference)

0.822

49

1

1 (reference)

0.335

 Present

190

4

0.33 (0.07–1.52)

182

12

0.59 (0.30–1.77)

191

3

0.77 (0.08–7.56)

193

1

0.25(0.02–4.13)

GSTM1

 null

129

3

1 (reference)

0.548

122

10

1 (reference)

 

131

1

a

132

0

a

 Present

108

4

1.59 (0.35–7.27)

105

7

0.81 (0.30–2.21)

0.686

109

3

110

2

GSTP1

 AA

141

4

1 (reference)

0.832

134

11

1 (reference)

0.150

142

3

1 (reference)

0.569

144

1

a

 AG

91

3

1.18 (0.26–5.39)

89

5

0.70 (0.23–2.07)

93

1

0.52 (0.05–5.04)

93

1

 GG

3

0

 

2

1

 

3

0

 

3

0

RCF1

 GG

71

3

1 (reference)

0.598

69

5

1 (reference)

0.759

73

1

1 (reference)

0.824

74

0

a

 GA

110

3

0.64 (0.13–3.29)

104

9

1.19 (0.38–3.72)

111

2

1.32 (0.12–14.8)

113

0

 AA

56

1

0.42 (0.04–4.17)

0.461

54

3

0.77 (0.18–3.35)

0.724

56

1

1.30 (0.08–21.3)

0.852

55

2

 AA vs. GA + GG

0.54 (0.06–4.57)

0.571

0.69 (0.19–2.48)

0.566

1.10 (0.11–10.74)

0.938

 

MTHFR

 CC

64

1

1 (reference)

 

66

1

1 (reference)

 

67

0

a

67

0

a

 CT

113

3

0.57 (0.11–2.89)

0.494

103

13

8.32 (1.06–65.2)

0.043

114

2

115

1

 TT

60

1

0.36 (0.04–3.51)

0.376

58

3

3.41 (0.35–33.7)

0.294

59

2

60

1

 TT vs. CT + CC

0.49 (0.06–4.17)

0.515

0.62 (0.17–2.25)

0.472

3.07 (0.42–22.3)

0.268

 

TS-TR

 2R/2R

84

2

1 (reference)

 

83

3

1 (reference)

 

85

1

1 (reference)

 

86

0

a

 2R/3R

74

4

0.44 (0.08–2.47)

0.352

68

10

0.25 (0.06–0.93)

0.038

76

2

0.45 (0.04–5.03)

0.514

78

0

 3R/3R

79

1

0.23 (0.03–2.14)

0.199

76

4

0.36 (0.11–1.19)

0.095

79

1

0.48 (0.04–5.42)

0.553

78

2

 3/3R vs. 2/3R + 2/2R

0.33 (0.04–2.82)

0.313

0.61 (0.19–1.94)

0.403

0.68 (0.07–6.64)

0.740

 
  1. OR Odds Ratio, CI Confidence Intervals
  2. aDue to the low number of events it was not always possible to perform the comparison test
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us